PT  - JOURNAL ARTICLE
AU  - OSAMU TAKAKUWA
AU  - TETSUYA OGURI
AU  - TAKEHIRO UEMURA
AU  - EIJI KUNII
AU  - MAKOTO NAKAO
AU  - HISATOSHI HIJIKATA
AU  - YUKO KAWAGUCHI
AU  - HIROTSUGU OHKUBO
AU  - MASAYA TAKEMURA
AU  - KEN MAENO
AU  - AKIO NIIMI
TI  - <em>ABCB1</em> Polymorphism as a Predictive Biomarker for Amrubicin-induced Neutropenia
DP  - 2014 Jul 01
TA  - Anticancer Research
PG  - 3517--3522
VI  - 34
IP  - 7
4099  - http://ar.iiarjournals.org/content/34/7/3517.short
4100  - http://ar.iiarjournals.org/content/34/7/3517.full
SO  - Anticancer Res2014 Jul 01; 34
AB  - Background: Amrubicin is a promising therapy for lung cancer, but is associated with a high incidence of severe neutropenia. The present study assessed the utility of ABCB1 and NAD(P)H quinone oxidoreductase 1 (NQO1) polymorphism as a predictor of amrubicin-induced neutropenia. Materials and Methods: Fifty-four Japanese lung cancer patients who received amrubicin chemotherapy were consecutively recruited and toxicities and SNPs (MDR1; C1236T, C3435T and G2677T/A, NQO1; C609T) were evaluated. Results: The incidence of neutropenia was higher in patients treated with 40 mg/m2 of amrubicin (n=32) compared to patients treated with 35 mg/m2 of amrubicin (n=22) (53.1% vs. 22.7%). Patients who were homogenous for the wild-type allele of C3435T were at significantly higher risk of neutropenia compared to patients with other genotypes. By contrast, the C609T genotype of NQO1 was not related to neutropenia. Conclusion: C3435T polymorphisms of ABCB1 might be able to predict severe amrubicin-induced neutropenia.